GCVI Summit 2018
Skip Content

14 November 2017

Fortuna Fix puts together $25m series B

Amgen Ventures contributed to a series B round for Fortuna Fix, which will use the funding for clinical trials and to expand manufacturing.

Author: Sam McCaffrey, Reporter

Canada-based regenerative medical technology developer Fortuna Fix has secured $25m in series B funding from invetsors including pharmaceutical firm Amgen’s corporate venturing arm, Amgen Ventures.